# Synlogic, Inc.: overview SYBX · OTC · CIK 1527599 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/sybx.md) · [Financials](/companies/sybx/financials.md) · [Filings](/companies/sybx/filings.md) · [Insiders](/companies/sybx/insiders.md) Latest reported revenue: [$0](/filings/0001193125-26-344789.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 11, 2026 (XBRL us-gaap:Revenues, accession 0001193125-26-344789). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [0.0](/filings/0001193125-25-280270.md) | [0.0 d](/filings/0001193125-26-104262.md) | [0.0](/filings/0001193125-26-224171.md) | [0.0](/filings/0001193125-26-344789.md) | [0.0](/filings/0001193125-25-280270.md) | [0.0 d](/filings/0001193125-26-104262.md) | [0.0](/filings/0001193125-26-224171.md) | [0.0](/filings/0001193125-26-344789.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.01)](/filings/0001193125-25-280270.md) | not reported | [0.03](/filings/0001193125-26-224171.md) | [(0.04)](/filings/0001193125-26-344789.md) | [(0.19)](/filings/0001193125-25-280270.md) | not reported | [0.05](/filings/0001193125-26-224171.md) | [(0.04)](/filings/0001193125-26-344789.md) | | Free cash flow | $k | [(648) d](/filings/0001193125-25-280270.md) | [(568) d](/filings/0001193125-26-104262.md) | [(1,601)](/filings/0001193125-26-224171.md) | [(399) d](/filings/0001193125-26-344789.md) | [(1,436) d](/filings/0001193125-25-280270.md) | [(923) d](/filings/0001193125-26-104262.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [1.8](/filings/0000950170-23-010428.md) | [1.2](/filings/0000950170-24-033146.md) | [3.4](/filings/0000950170-25-034820.md) | [0.0](/filings/0001193125-26-104262.md) | [0.0](/filings/0001193125-26-104262.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(3464.4%)](/filings/0000950170-23-010428.md) | [(5713.5%)](/filings/0000950170-24-033146.md) | [(1636.3%)](/filings/0000950170-25-034820.md) | [(511875.0%)](/filings/0001193125-26-104262.md) | not reported | | Net margin | % | [(3452.7%)](/filings/0000950170-23-010428.md) | [(5605.7%)](/filings/0000950170-24-033146.md) | [(1817.7%)](/filings/0000950170-25-034820.md) | [(291987.5%)](/filings/0001193125-26-104262.md) | not reported | | Diluted EPS | $ per share | [(1.09)](/filings/0000950170-23-010428.md) | [(13.83)](/filings/0000950170-24-033146.md) | [(9.42)](/filings/0000950170-25-034820.md) | [(1.92)](/filings/0001193125-26-104262.md) | [(0.08)](/filings/0001193125-26-104262.md) | | Free cash flow | $m | [(52.9)](/filings/0000950170-23-010428.md) | [(57.6)](/filings/0000950170-24-033146.md) | [(51.8)](/filings/0000950170-25-034820.md) | [(31.7)](/filings/0001193125-26-104262.md) | [(4.4)](/filings/0001193125-26-104262.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/sybx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [DRW Securities, LLC](/funds/1481986.md) | 2026-06-30 | $16.7k | 23,763 | | Unchanged | ## Recent filings [All 617 filings](/companies/sybx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-11 | 16:30 ET | [10-Q](/filings/0001193125-26-344789.md) | Quarterly report, period 2026-06-30 | 0001193125-26-344789 | | 2026-07-29 | 19:40 ET | [SCHEDULE 13D/A](/filings/0001072613-26-000599.md) | Ownership report, active investor, amended | 0001072613-26-000599 | | 2026-07-29 | 16:18 ET | [SCHEDULE 13D/A](/filings/0000921895-26-001889.md) | Ownership report, active investor, amended | 0000921895-26-001889 | | 2026-07-29 | 07:19 ET | [8-K](/filings/0001193125-26-322160.md) | 1.01 Entry into a material agreement; 3.03 Change to security holders’ rights; 5.01 Change in control; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-322160 | | 2026-05-14 | 16:30 ET | [10-Q](/filings/0001193125-26-224171.md) | Quarterly report, period 2026-03-31 | 0001193125-26-224171 | | 2026-04-30 | 16:29 ET | [10-K/A](/filings/0001193125-26-197468.md) | Annual report, amended, period 2025-12-31 | 0001193125-26-197468 | | 2026-04-06 | 16:15 ET | [SCHEDULE 13D/A](/filings/0000921895-26-000926.md) | Ownership report, active investor, amended | 0000921895-26-000926 | | 2026-03-12 | 16:30 ET | [10-K](/filings/0001193125-26-104262.md) | Annual report, period 2025-12-31 | 0001193125-26-104262 | | 2026-01-29 | 09:00 ET | [8-K/A](/filings/0001193125-26-028333.md) | 3.01 Delisting notice; 8.01 Other events | 0001193125-26-028333 | | 2026-01-20 | 09:00 ET | [8-K](/filings/0001193125-26-016040.md) | 3.01 Delisting notice | 0001193125-26-016040 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-104262.md), filed Mar 12, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/1cee2e13-3076-48dc-93a6-c2206c4dc4a3) ## About the filer - CIK: 1527599 - Tickers: SYBX - Exchange: OTC - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.